Manufacturing of an Enterotoxigenic Escherichia coli (ETEC) Vaccine for the Treatment of Bacterial Diarrhea for Use in Pivotal Clinical Trials

United States Army Medical Materiel Development Activity seeks to clinically evaluate and achieve U.S. Food and Drug Administration (FDA) licensure of a multivalent vaccine to induce active immunity against ETEC for the prevention of traveler’s diarrhea to protect the Force (population 18-55 years of age). United States Army Medical Research Acquisition Activity is conducting market research to determine whether a commercial solution can be provided to meet requirements for developing a FDA licensed ETECV for the prevention of bacterial-induced diarrhea. This market research may also assist with the further development and/or refinement of the requirements.